Status:
COMPLETED
A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis
Lead Sponsor:
Novartis
Conditions:
Secondary Progressive Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
RESYZE was a non-interventional/observational, retrospective, multi-center study conducted in 28 public and private hospitals in Spain, assessing secondary progressive multiple sclerosis (SPMS) patien...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with SPMS, as diagnosed by a physician, who started siponimod treatment at least 12 months before (during the start of the treatment period: from April 2021 to September 2022), regardless of whether they continued treatment or they did not.
- Patients who received at least 1 dose of siponimod treatment for SPMS with a 12-month observation period.
- Availability of the data for at least 12 months after siponimod initiation.
- Exclusion criteria:
- Patients with any contraindication to siponimod, according to applicable Summary of Product Characteristics (SmPC).
- Patients included in any clinical trial at any moment of the study period.
Exclusion
Key Trial Info
Start Date :
November 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 8 2023
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT06588387
Start Date
November 3 2022
End Date
September 8 2023
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936